Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials

JAMA - Journal of the American Medical Association

Volumn 323, Issue 5, 2020, Pages 432-443

  Wolf, Myles ^a   Rubin, Janet ^b   Achebe, Maureen ^c   Econs, Michael J ^d   Peacock, Munro ^d   Imel, Erik A ^d   Thomsen, Lars L ^e   Carpenter, Thomas O ^f   Weber, Thomas ^g   Brandenburg, Vincent ^h   Zoller, Heinz ⁱ  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Pharmacosmos AS   (Denmark)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Rhein Maas Klinikum GmbH   (Germany)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON ISOMALTOSE; PARATHYROID HORMONE; PHOSPHATE;

AGE; ARTICLE; BONE METABOLISM; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FERRITIN BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; MINERAL METABOLISM; NAUSEA; OPEN STUDY; OUTPATIENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIDE EFFECT; STUDY DESIGN; UNITED STATES;

EID: 85078905387     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2019.22450     Document Type: Article

References (35)

1. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015; 372 (19): 1832-1843. doi: 10.1056/NEJMra1401038 25946282
2. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016; 387 (10021): 907-916. doi: 10.1016/S0140-6736(15)60865-0 26314490
3. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: Clinical and pathophysiological insights. Int J Hematol. 2018; 107 (1): 16-30. doi: 10.1007/s12185-017-2373-3 29196967
4. Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous irons: From basic science to clinical practice. Pharmaceuticals (Basel). 2018; 11 (3): 82. doi: 10.3390/ph11030082 30150598
5. Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017; 92 (3): 286-291. doi: 10.1002/ajh.24633 28052413
6. Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: A randomized controlled trial. Vox Sang. 2017; 112 (3): 219-228. doi: 10.1111/vox.12477 28198084
7. Onken JE, Bregman DB, Harrington RA, A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014; 54 (2): 306-315. 23772856
8. Onken JE, Bregman DB, Harrington RA, Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial. Nephrol Dial Transplant. 2014; 29 (4): 833-842. doi: 10.1093/ndt/gft251 23963731
9. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013; 28 (8): 1793-1803. doi: 10.1002/jbmr.1923 23505057
10. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018; 3 (23):
11. Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020; 16 (1): 7-19. doi: 10.1038/s41581-019-0189-5 31519999
12. Subramanian R, Khardori R. Severe hypophosphatemia: Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). 2000; 79 (1): 1-8. doi: 10.1097/00005792-200001000-00001 10670405
13. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: An emerging complication. Curr Opin Nephrol Hypertens. 2017; 26 (4): 266-275. doi: 10.1097/MNH.0000000000000329 28399017
14. Auerbach M, Lykke LL. A single infusion of iron isomaltoside 1000 allows a more rapid hemoglobin increment than multiple doses of iron sucrose with a similar safety profile in patients with iron deficiency anemia. Blood. 2018; 132 (suppl 1): 2334. doi: 10.1182/blood-2018-99-110199
15. Emrich IE, Lizzi F, Seiler-Mußler S, Hypophosphatemia after high dosage iron substitution with ferric carboxymaltose (FCM) and iron isomaltoside (IM): The randomised controlled Home Afers 1 trial. Blood. 2018; 132 (suppl 1): 3627. doi: 10.1182/blood-2018-99-114386
16. US Food and Drug Administration. Highlights of prescribing information: Injectafer (ferric carboxymaltose injection). Vifor (International) Inc, Switzerland. https://www.accessdata.fda.gov/drugsatfda-docs/label/2018/203565s005lbl.pdf. Revised January 2018. Accessed October 22, 2019.
17. Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: The PROFOUND trial. Pharmacotherapy. 2016; 36 (4): 402-414. doi: 10.1002/phar.1729 26927900
18. Dahlerup JF, Jacobsen BA, van der Woude J, Bark LÅ, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016; 51 (11): 1332-1338. doi: 10.1080/00365521.2016.1196496 27326766
19. Reinisch W, Staun M, Tandon RK, A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013; 108 (12): 1877-1888. doi: 10.1038/ajg.2013.335 24145678
20. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion. 2009; 49 (12): 2719-2728. doi: 10.1111/j.1537-2995.2009.02327.x 19682342
21. Favrat B, Balck K, Breymann C, Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women: PREFER a randomized, placebo-controlled study. PLoS One. 2014; 9 (4):
22. Yan X, Su XG. Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions. Stat Biopharm Res. 2010; 2 (3): 329-335. doi: 10.1198/sbr.2009.0049
23. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008; 118 (12): 3820-3828. doi: 10.1172/JCI36479 19033649
24. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989; 320 (15): 980-991. doi: 10.1056/NEJM198904133201506 2648151
25. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357 (3): 266-281. doi: 10.1056/NEJMra070553 17634462
26. Potts JT. Parathyroid hormone: Past and present. J Endocrinol. 2005; 187 (3): 311-325. doi: 10.1677/joe.1.06057 16423810
27. Farrow EG, Yu X, Summers LJ, Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA. 2011; 108 (46): E1146-E1155. doi: 10.1073/pnas.1110905108 22006328
28. Shimada T, Hasegawa H, Yamazaki Y, FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19 (3): 429-435. doi: 10.1359/JBMR.0301264 15040831
29. Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018; 2018:
30. Schaefer B, Glodny B, Zoller H. Blood and bone loser. Gastroenterology. 2017; 152 (6): E5-e6. doi: 10.1053/j.gastro.2016.09.050 28384445
31. Urbina T, Belkhir R, Rossi G, Iron supplementation-induced phosphaturic osteomalacia: FGF23 is the culprit. J Bone Miner Res. 2018; 33 (3): 540-542. doi: 10.1002/jbmr.3369 29281120
32. Burckhardt P. Iron-induced osteomalacia. Osteologie. 2018; 27 (1): 20-23.
33. Nagata Y, Imanishi Y, Ishii A, Evaluation of bone markers in hypophosphatemic rickets/osteomalacia. Endocrine. 2011; 40 (2): 315-317. doi: 10.1007/s12020-011-9512-z 21822687
34. Peach H, Compston JE, Vedi S, Horton LWL. Value of plasma calcium, phosphate, and alkaline phosphatase measurements in the diagnosis of histological osteomalacia. J Clin Pathol. 1982; 35 (6): 625-630. doi: 10.1136/jcp.35.6.625 7085914
35. Detlie TE, Lindstrøm JC, Jahnsen ME, Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019; 50 (4): 397-406. doi: 10.1111/apt.15386 31264261